Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11985668 | 0.99 | GAA (0.66) | GAASMN1; SMN2CYP2D6POLBKMT2A | |
| SCHEMBL16511120 | 0.88 | GAA (0.81) | GAASMN1; SMN2CYP2D6POLBKMT2A | |
| SCHEMBL13065455 | 0.87 | GAA (0.67) | GAASMN1; SMN2CYP2D6POLBKMT2A | |
| SCHEMBL16511117 | 0.86 | GAA (0.83) | GAASMN1; SMN2CYP2D6POLBKMT2A | |
| SCHEMBL2822477 | 0.81 | KMT2A (0.76) | GAASMN1; SMN2CYP2D6POLBKMT2A | |
| SCHEMBL16511119 | 0.79 | ALDH1A1 (0.73) | GAASMN1; SMN2CYP2D6POLBKMT2A | |
| SCHEMBL16511225 | 0.78 | ALDH1A1 (0.75) | GAASMN1; SMN2CYP2D6POLBKMT2A | |
| SCHEMBL2822487 | 0.75 | GAA (0.58) | GAASMN1; SMN2CYP2D6POLBKMT2A | |
| SCHEMBL14853581 | 0.74 | HASPIN (0.53) | GAACYP2D6POLBHRH3ALDH1A1 | |
| SCHEMBL14853590 | 0.74 | CD274 (0.64) | POLBKMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969571-B2 | Biphenyl derivatives | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140235864-A1 | BIPHENYL DERIVATIVES | THERAVANCE, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20130150404-A1 | BIPHENYL DERIVATIVES | THERAVANCE, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-8242135-B2 | Biphenyl derivatives | THERAVANCE, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8143277-B2 | Method of using compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110312994-A1 | BIPHENYL DERIVATIVES | THERAVANCE, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-8008278-B2 | Diarylmethyl and related compounds | THERAVANCE, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-7879879-B2 | Biphenyl derivatives | THERAVANCE, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20110015152-A1 | DIARYLMETHYL AND RELATED COMPOUNDS | THERAVANCE, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-7829728-B2 | Diarymethyl and related compounds | THERAVANCE, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7507751-B2 | Biphenyl-2-ylcarbamic acid 1-{7-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]heptyl}piperidin-4-yl ester; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist; bronchodilator agent; pulmonary disorders, chronic obstructive pulmonary disease and asthma | THERAVANCE, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20080114030-A1 | Diarymethyl and related compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-05-15 | — | — | US | disclosed |
| US-7355046-B2 | Chronic obstructive pulmonary dusease; asthma | THERAVANCE, INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7345175-B2 | Biphenyl derivatives | THERAVANCE, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20080015220-A1 | Biphenyl-2-ylcarbamic acid 1-{7-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]heptyl}piperidin-4-yl ester; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist; bronchodilator agent; pulmonary disorders, chronic obstructive pulmonary disease and asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-01-17 | — | — | US | disclosed |
| US-7317102-B2 | Diarylmethyl and related compounds | THERAVANCE, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-20070276003-A1 | Biphenyl-2-ylcarbamic acid 1-{7-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]heptyl}piperidin-4-yl ester; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist; bronchodilator agent; pulmonary disorders, chronic obstructive pulmonary disease and asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-11-29 | — | — | US | disclosed |
| US-20070208176-A1 | Biphenyl-2-ylcarbamic acid 1-{7-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]heptyl}piperidin-4-yl ester; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist; bronchodilator agent; pulmonary disorders, chronic obstructive pulmonary disease and asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-09-06 | — | — | US | disclosed |
| US-20070088054-A1 | e.g. 3-(4-{[6-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethyl}amino)-hexyl]oxy}butyl)benzenesulfonamide; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist activity; bronchodilator agent; pulmonary disorders: chronic obstructive pulmonary disease; asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-04-19 | — | — | US | disclosed |
| US-20070037984-A1 | Biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]methyl}-5-methoxyphenyl-carbamoyl)ethyl]piperidin-4-yl ester; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist; bronchodilator agent; pulmonary disorders, asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037984-A1 | Biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]methyl}-5-methoxyphenyl-carbamoyl)ethyl]piperidin-4-yl ester; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist; bronchodilator agent; pulmonary disorders, asthma | ADRB2, ADRA2B, ADRB1 | GAA 3941/4885SMN1; SMN2 3672/4885CYP2D6 629/4885 |
| US-20070088054-A1 | e.g. 3-(4-{[6-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethyl}amino)-hexyl]oxy}butyl)benzenesulfonamide; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist activity; bronchodilator agent; pulmonary disorders: chronic obstructive pulmonary disease; asthma | ADRB2, ADRB3, ADRB1 | GAA 3297/4885SMN1; SMN2 3354/4885CYP2D6 325/4885 |
| US-20140235864-A1 | BIPHENYL DERIVATIVES | ADRB1, ADRB2, ADRB3 | GAA 4300/4885SMN1; SMN2 3873/4885CYP2D6 222/4885 |
| US-20080114030-A1 | Diarymethyl and related compounds | ADRB2, ADRB1, ADRA2B | GAA 4549/4885SMN1; SMN2 3574/4885CYP2D6 554/4885 |
| US-20070276003-A1 | Biphenyl-2-ylcarbamic acid 1-{7-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]heptyl}piperidin-4-yl ester; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist; bronchodilator agent; pulmonary disorders, chronic obstructive pulmonary disease and asthma | ADRB2, ADRA2B, ADRB1 | GAA 3689/4885SMN1; SMN2 3760/4885CYP2D6 539/4885 |
| US-20080015220-A1 | Biphenyl-2-ylcarbamic acid 1-{7-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]heptyl}piperidin-4-yl ester; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist; bronchodilator agent; pulmonary disorders, chronic obstructive pulmonary disease and asthma | ADRB2, ADRA2B, ADRB1 | GAA 3689/4885SMN1; SMN2 3760/4885CYP2D6 539/4885 |
| US-20110015152-A1 | DIARYLMETHYL AND RELATED COMPOUNDS | ADRB2, ADRB1, ADRA2B | GAA 4601/4885SMN1; SMN2 3569/4885CYP2D6 698/4885 |
| US-20070208176-A1 | Biphenyl-2-ylcarbamic acid 1-{7-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]heptyl}piperidin-4-yl ester; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist; bronchodilator agent; pulmonary disorders, chronic obstructive pulmonary disease and asthma | ADRB2, ADRA2B, ADRB1 | GAA 3689/4885SMN1; SMN2 3760/4885CYP2D6 539/4885 |
| US-20130150404-A1 | BIPHENYL DERIVATIVES | ADRB1, ADRB2, ADRB3 | GAA 4325/4885SMN1; SMN2 3885/4885CYP2D6 224/4885 |
| US-20110312994-A1 | BIPHENYL DERIVATIVES | ADRB1, ADRB2, ADRB3 | GAA 4300/4885SMN1; SMN2 3873/4885CYP2D6 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.